Literature DB >> 22252007

Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly.

Roberto Gasparini1, Daniela Amicizia, Piero Luigi Lai, Donatella Panatto.   

Abstract

Influenza epidemics and pandemics carry a heavy socioeconomic burden. Hospitalization and treatment are more often necessary in high-risk patients, such as the elderly. However, the impact of influenza is not negligible even in adults, mainly because of lost productivity. The World Health Organization estimates that seasonal influenza causes 250,000-500,000 deaths worldwide each year; however, mortality may be very high in pandemic periods. Many estimates of the costs of seasonal influenza have been made in various socioeconomic contexts. For instance, among the adult population in Italy, a cost of €940.39 per case has been estimated. In the US, the average annual influenza burden in 18-49-y-old adults without underlying medical conditions is judged to include approximately 32,000 hospitalizations and 680 deaths. Estimating the influenza burden is a useful aid to determining the best influenza vaccination strategy and preventive and clinical treatments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22252007     DOI: 10.4161/hv.8.1.17622

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  52 in total

1.  Costs associated with influenza-related hospitalization in the elderly.

Authors:  Núria Torner; Encarna Navas; Núria Soldevila; Diana Toledo; Gemma Navarro; Aurea Morillo; Maria José Pérez; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

Review 2.  Epidemiology, ecology and gene pool of influenza A virus in Egypt: will Egypt be the epicentre of the next influenza pandemic?

Authors:  E M Abdelwhab; Ahmed S Abdel-Moneim
Journal:  Virulence       Date:  2015       Impact factor: 5.882

3.  A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.

Authors:  Giovanni Della Cioppa; Uwe Nicolay; Kelly Lindert; Geert Leroux-Roels; Frédéric Clement; Flora Castellino; Cristina Galli; Nicola Groth; Yotam Levin; Giuseppe Del Giudice
Journal:  Hum Vaccin Immunother       Date:  2014-04-14       Impact factor: 3.452

Review 4.  Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview.

Authors:  Nicola Luigi Bragazzi; Andrea Orsi; Filippo Ansaldi; Roberto Gasparini; Giancarlo Icardi
Journal:  Hum Vaccin Immunother       Date:  2016-05-31       Impact factor: 3.452

Review 5.  Influenza vaccination in the elderly.

Authors:  Jan Smetana; Roman Chlibek; Jana Shaw; Miroslav Splino; Roman Prymula
Journal:  Hum Vaccin Immunother       Date:  2017-08-04       Impact factor: 3.452

6.  Seasonal influenza vaccination among older adults in Jordan: prevalence, knowledge, and attitudes.

Authors:  Mera Ababneh; Mutaz Jaber; Abeer Rababa'h; Faris Ababneh
Journal:  Hum Vaccin Immunother       Date:  2020-02-11       Impact factor: 3.452

7.  Expert-novice differences in mental models of viruses, vaccines, and the causes of infectious disease.

Authors:  Benjamin D Jee; David H Uttal; Amy Spiegel; Judy Diamond
Journal:  Public Underst Sci       Date:  2013-08-19

8.  Strategies in recommending influenza vaccination in Europe and US.

Authors:  Caterina Rizzo; Giovanni Rezza; Walter Ricciardi
Journal:  Hum Vaccin Immunother       Date:  2018-01-09       Impact factor: 3.452

9.  A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.

Authors:  Keith S Reisinger; Sandra J Holmes; Paola Pedotti; Ashwani Kumar Arora; Maria Lattanzi
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 10.  Development and applications of single-cycle infectious influenza A virus (sciIAV).

Authors:  Aitor Nogales; Steven F Baker; William Domm; Luis Martínez-Sobrido
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.